Table 2.
Treatment and outcome of children with Influenza and neurological complications admitted to the Sydney Children's Hospitals network during the 2017 Influenza season.
| Outcomes | IAEa (n = 11) | SEb (n = 11) | p-Value |
|---|---|---|---|
| Admitted to intensive care | 9 (82) | 5 (45) | 0.18 |
| Required mechanical ventilation | 7 (64) | 2 (18) | 0.08 |
| Treatmentc | |||
| Oseltamivir | 7 (64) | 6 (55) | 1.0 |
| 3rd generation cephalosporin | 11 (100) | 8 (73) | 0.21 |
| Aciclovir | 8 (73) | 6 (55) | 0.66 |
| Intravenous immunoglobulin | 7 (64) | 0 (0) | 0.004 |
| High dose corticosteroids | 9 (82) | 0 (0) | <0.001 |
| Plasmapheresis | 1 (9) | 0 (0) | 1.0 |
| Anticonvulsant | 8 (73) | 11 (100) | 0.21 |
| Days in ICU (mean, range) | 7.7 (1–37) | 2 (1–3) | 0.03 |
| Days in hospital (mean, range) | 33.5 (5–108) | 4.8 (2–14) | 0.001 |
| Outcome at discharge | |||
| Death | 1 (9) | 0 (0) | 1.0 |
| Abnormal/Poord | 7 (64) | 0 (0) | 0.004 |
| Mean mRS at admission | 0.2 | 1.7 | 0.086 |
| Mean mRS at discharge | 3.3 | 2.1 | 0.126 |
| Mean change in mRS | 3.1 | 0.4 | 0.001 |
Tests used – Fisher exact for categorical and Mann–Whitney for continuous data points.
a
IAE: influenza related encephalopathy.
b
SE: status epilepticus.
c
Treatment received during hospital admission.
d
Defined as an increase of more than 2 points on mRS (new disability or worsening of preexisting disability by >2 points).